Doctor's Notes

Contact Dermatitis Patterns in 236 Professional Musicians

Dr. Arsy #003 Life in Motion editorial illustration: Professional musicians contact-dermatitis evidence

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, activity or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

The question behind this paper

This review looks at professional instrument contact and performance-related skin disease. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.

Study snapshot

Study element Reported detail
Population 236 professional musicians in the IVDK patch-test network, compared with non-musician patients
Design Retrospective network analysis from 1997 through 2017
Timepoint Twenty years of referred-patient data
Key result Facial dermatitis was recorded in 23.7% of musicians versus 15.7% of controls, while leg dermatitis was 5.1% versus 10.7%; an occupational background was confirmed in 8.9% of musician cases.

How to interpret the result

The study describes where disease appeared and how often occupational relevance was confirmed in a referral network. It should not be read as prevalence among all musicians.

Important limitation: All participants were referred for patch testing, the comparison group was not a workforce sample, and site differences do not prove an instrument caused dermatitis.

Questionnaires, examinations, patch tests, chemical analyses and trial models answer different questions. A positive screening result, symptom report or association can guide a next step, but it does not diagnose the cause of one person’s rash. Clinician-directed testing is interpreted alongside timing, distribution and verified exposures.

Questions to ask next

  • What exactly was measured: reported symptoms, visible signs, allergy, work loss, performance or quality of life?
  • Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
  • Did the design compare groups or follow change over time, and what factors could still explain the difference?
  • Would occupational-health review, clinician examination or clinician-directed testing change the practical plan?
  • What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?

Primary and authoritative sources

PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.

Where a cosmetic moisturizer fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.

Bottom line

The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.

← Back to Doctor's Notes